Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBITDA Margin (2016 - 2023)

Historic EBITDA Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 23146.22%.

  • Spyre Therapeutics' EBITDA Margin fell 195585400.0% to 23146.22% in Q2 2023 from the same period last year, while for Mar 2024 it was 39428.92%, marking a year-over-year decrease of 326352800.0%. This contributed to the annual value of 27347.97% for FY2023, which is 237077400.0% down from last year.
  • Per Spyre Therapeutics' latest filing, its EBITDA Margin stood at 23146.22% for Q2 2023, which was down 195585400.0% from 9497.98% recorded in Q1 2023.
  • Spyre Therapeutics' EBITDA Margin's 5-year high stood at 55.88% during Q2 2021, with a 5-year trough of 23146.22% in Q2 2023.
  • In the last 3 years, Spyre Therapeutics' EBITDA Margin had a median value of 3587.68% in 2022 and averaged 6777.45%.
  • In the last 5 years, Spyre Therapeutics' EBITDA Margin plummeted by -35318000bps in 2022 and then tumbled by -195585400bps in 2023.
  • Spyre Therapeutics' EBITDA Margin (Quarter) stood at 560.98% in 2021, then plummeted by -1933bps to 11405.95% in 2022, then tumbled by -103bps to 23146.22% in 2023.
  • Its EBITDA Margin was 23146.22% in Q2 2023, compared to 9497.98% in Q1 2023 and 11405.95% in Q4 2022.